LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Inicio・Lista de Acciones・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Cerrado

4.28 -3.39

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.25

Máximo

4.47

Métricas clave
By Trading Economics
Ingresos	5.5M -28M
Ventas	8.2M 13M
Margen de beneficio	-208.694
Empleados	172
EBITDA	8.7M -27M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+228.92% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-26M 229M
Apertura anterior	7.67
Cierre anterior	4.28

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

3.17 / 3.4644 Soporte y Resistencia

Voyager Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 mar 2026, 21:37 UTC

Adquisiciones, fusiones, absorciones

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Noticias de Eventos Importantes

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Adquisiciones, fusiones, absorciones

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Charlas de Mercado

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Charlas de Mercado

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Adquisiciones, fusiones, absorciones

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Noticias de Eventos Importantes

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Charlas de Mercado

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Noticias de Eventos Importantes

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Charlas de Mercado

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Charlas de Mercado

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Noticias de Eventos Importantes

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Charlas de Mercado

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Noticias de Eventos Importantes

Trump Ends News Conference

Comparación entre iguales

Cambio de precio

Voyager Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

228.92% repunte

Estimación a 12 meses

Media 14.67 USD 228.92%

Máximo 25 USD

Mínimo 8 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Voyager Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Voyager Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

3.17 / 3.4644Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.